Alterity Therapeutics Limited
ATHE
$3.43
-$0.02-0.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 75.84% | 70.46% | 75.89% | 72.58% | -15.53% |
| Total Revenue | 75.84% | 70.46% | 75.89% | 72.58% | -15.53% |
| Cost of Revenue | 56.52% | 51.64% | -47.03% | -47.93% | -34.49% |
| Gross Profit | 76.64% | 71.22% | 83.08% | 79.67% | -14.51% |
| SG&A Expenses | 55.66% | 50.91% | -21.89% | -23.35% | 60.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 241.30% | 231.22% | 1,860.00% | 1,820.00% | 1,433.33% |
| Total Operating Expenses | 45.86% | 41.41% | -29.51% | -30.83% | 7.33% |
| Operating Income | -39.49% | -35.22% | 46.70% | 47.70% | -13.88% |
| Income Before Tax | -34.15% | -30.06% | 62.06% | 62.77% | -10.22% |
| Income Tax Expenses | -- | -- | 43.42% | 40.13% | -- |
| Earnings from Continuing Operations | -35.02% | -30.89% | 61.67% | 62.39% | -10.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.02% | -30.89% | 61.67% | 62.39% | -10.22% |
| EBIT | -39.49% | -35.22% | 46.70% | 47.70% | -13.88% |
| EBITDA | -39.77% | -35.50% | 46.72% | 47.72% | -13.95% |
| EPS Basic | 25.00% | 40.00% | 77.78% | 77.78% | 50.00% |
| Normalized Basic EPS | 33.33% | 33.33% | 60.00% | 60.00% | 40.00% |
| EPS Diluted | 40.00% | 40.00% | 77.78% | 77.78% | 37.50% |
| Normalized Diluted EPS | 33.33% | 33.33% | 60.00% | 60.00% | 40.00% |
| Average Basic Shares Outstanding | 91.58% | 91.58% | 56.02% | 56.02% | 112.26% |
| Average Diluted Shares Outstanding | 91.58% | 91.58% | 56.02% | 56.02% | 112.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |